Effectiveness of Noninvasive Fibrosis Markers for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B and Chronic Hepatitis B+D Induced Cirrhosis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Sahin T; Serin A; Emek E; Bozkurt B; Arikan BT; Tokat Y
  • Source:
    Transplantation proceedings [Transplant Proc] 2019 Sep; Vol. 51 (7), pp. 2397-2402. Date of Electronic Publication: 2019 Aug 08.
  • Publication Type:
    Evaluation Study; Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Elsevier Science Inc Country of Publication: United States NLM ID: 0243532 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2623 (Electronic) Linking ISSN: 00411345 NLM ISO Abbreviation: Transplant Proc Subsets: MEDLINE
    • Publication Information:
      Publication: New York, N.Y. : Elsevier Science Inc.
      Original Publication: New York Stratton.
    • Subject Terms:
      Carcinoma, Hepatocellular/*virology ; Hepatitis B, Chronic/*complications ; Hepatitis D, Chronic/*complications ; Liver Cirrhosis/*complications ; Liver Neoplasms/*virology; Adult ; Biomarkers/analysis ; Female ; Humans ; Liver Cirrhosis/virology ; Male ; Middle Aged ; Predictive Value of Tests ; Retrospective Studies ; Treatment Outcome
    • Abstract:
      Purpose: Despite advances in prevention techniques, screening, and new technologies in both diagnosis and treatment, the incidence and mortality of hepatocellular carcinoma (HCC) continue to rise. To obtain the best treatment result for HCC, early diagnosis is the key. In this study, we investigated the accuracy of noninvasive fibrosis markers, which have been typically used to predict liver fibrosis in recent years, in the prediction of HCC development in patients with chronic hepatitis B and chronic hepatitis B + D-induced cirrhosis.
      Methods: Between 2004 and 2018, 1216 patients with chronic liver disease were retrospectively reviewed, and 331 patients (27%) with hepatitis B and hepatitis B+D virus-related cirrhosis were enrolled in our study. Patients were divided into 2 groups based on HCC diagnosis (HCC and non-HCC group). Eleven noninvasive fibrosis markers were evaluated in the groups. These markers included 3 alpha-fetoprotein (AFP)-based models (PAPAS index, Fibro-alpha, and BRC score) and 8 non-AFP based models (Lok index, FIB-4, Fibro-O index, APRI, King's score, Forns index, Bonacini score, and HUI model) for each Child-Pugh score in the prediction of HCC.
      Results: AFP-based models were higher in HCC group patients, and statistically significant outcomes were detected with these methods in each Child-Pugh score group for HCC prediction (P < .05). Non-AFP based-methods showed different and inconsistent results in each Child-Pugh score group.
      Conclusion: These easily applied fibrosis markers, particularly AFP-based models, may provide an effective, simple, and low-cost way to predict HCC development in patients with hepatitis B and hepatitis B + D cirrhosis.
      (Copyright © 2019 Elsevier Inc. All rights reserved.)
    • Accession Number:
      0 (Biomarkers)
    • Publication Date:
      Date Created: 20190813 Date Completed: 20191224 Latest Revision: 20191224
    • Publication Date:
      20240628
    • Accession Number:
      10.1016/j.transproceed.2019.01.193
    • Accession Number:
      31402255